Hybridoma

Short answer

A hybridoma is an artificial hybrid cell line created by fusing an antibody-producing B lymphocyte with an immortal myeloma cell. This fusion combines the antigen specificity of primary B cells with the unlimited proliferative lifespan of myeloma cells, allowing laboratories to produce permanent, continuous supplies of uniform monoclonal antibodies for diagnostic assays, therapeutics, and biomedical research.

Definition and scope

The term hybridoma blends “hybrid” (cellular fusion of two parent lineages) with the oncology suffix “-oma” (denoting the tumor-derived myeloma partner). Pioneered in 1975 by Georges Köhler and César Milstein, hybridoma technology earned the 1984 Nobel Prize in Physiology or Medicine by solving a fundamental challenge in immunology: primary antibody-secreting B lymphocytes undergo terminal differentiation and die within days in vitro, whereas myeloma cells divide indefinitely but lack antigen-specific antibody secretion.

By fusing both lineages into a single somatic hybrid, researchers generate stable lines that inherit the rearranged immunoglobulin genes of the immunized B cell and the immortal replication machinery of the myeloma. Hybridomas serve as the classical engine for producing uniform monoclonal reagents used in ELISA screening assays, flow cytometry, immunohistochemistry, and clinical diagnostics.

How it works or how it is used in practice

Generating hybridomas follows four core stages: animal immunization, somatic cell fusion, biochemical selection, and single-cell cloning.

1. Immunization and B Cell Isolation

Mice (typically BALB/c) are immunized with a target antigen and adjuvant to drive in vivo affinity maturation. Spleen B lymphocytes expressing high-affinity surface antibodies are harvested once serum titers peak.

2. Cell Fusion and HAT Selection

Isolated spleen B cells are mixed with non-secreting, immortal myeloma partner cells (such as SP2/0-Ag14 or NS0) and fused using polyethylene glycol (PEG) or electrofusion. The resulting mixture contains unfused cells, homotypic fusions, and heterotypic hybridomas.

To eliminate unwanted cells, the culture is placed in HAT selection medium (Hypoxanthine, Aminopterin, and Thymidine):

• Aminopterin inhibits dihydrofolate reductase (DHFR), blocking de novo purine and pyrimidine nucleotide synthesis across all cells.
• Cells must survive via nucleotide salvage pathways using hypoxanthine (via HGPRT) and thymidine (via thymidine kinase).
• The myeloma fusion partner lacks functional hypoxanthine-guanine phosphoribosyltransferase (HGPRT−). Because their de novo pathway is blocked and salvage is broken, unfused myeloma cells die.
• Unfused primary spleen B cells possess HGPRT but senesce naturally within 5 to 7 days.
• Hybridomas survive: They inherit functional HGPRT from the spleen B cell and replicative immortality from the myeloma, making them the only cells capable of dividing in HAT medium.

3. Screening and Limiting Dilution Cloning

Surviving colonies are transitioned to HT medium (hypoxanthine and thymidine only) to clear residual aminopterin. Supernatants are screened by ELISA or flow cytometry. High-affinity clones undergo limiting dilution (plating at 0.5 cells per well in 96-well plates) to guarantee single-cell monoclonality.

Types or related concepts

Monoclonal antibodies from hybridomas represent one of several established reagent classes. The table below compares hybridomas with alternative generation platforms based on peer-reviewed discovery literature.

Platform	Generation Mechanism	Heavy/Light Chain Pairing	Genetic and Sequence Stability	Production Host
Hybridoma Monoclonal	In vivo animal immunization, spleen B cell fusion with myeloma, and HAT selection.	Natural cognate pairing via in vivo immune repertoire.	Prone to karyotypic drift; requires early master cryopreservation banking.	Mammalian suspension or semi-adherent culture (RPMI-1640 or IMDM).
Polyclonal Antiserum	Repeated animal immunization followed by serum extraction.	Heterogeneous mixture targeting diverse epitopes.	Finite donor animal lifespan; batch-to-batch titer variability.	In vivo animal serum (rabbit, sheep, goat).
Recombinant / Phage Display	In vitro biopanning of antibody fragment libraries displayed on bacteriophage.	Combinatorial pairing unless derived from single B cell sequencing.	Sequence-defined in expression plasmids; zero clonal drift.	Recombinant expression in CHO, HEK293, or microbial hosts.
Transgenic Mouse mAb	Immunization of mice engineered with human Ig loci, followed by hybridoma fusion.	Natural cognate pairing with fully human variable domains.	Hybridoma drift risk; rescued by sequencing into recombinant vectors.	Hybridoma culture or downstream recombinant CHO production.

For guidance on choosing between polyclonal and monoclonal formats for analytical assays, consult our guide to polyclonal versus monoclonal antibodies.

Where it matters for labs, clinics or supply decisions

Hybridoma lines require disciplined cell culture management, media formulation, and regulatory quality control.

Media Formulation and Serum Management

Per the ATCC Animal Cell Culture Guide, hybridomas require tailored basal media:

• IMDM (Iscove’s Modified Dulbecco’s Medium): Enriched with additional amino acids, vitamins, and potassium nitrate compared to standard DMEM, supporting robust hybridoma expansion.
• RPMI-1640: The industry-standard basal formulation for maintenance and antibody production phases.
• Serum Selection: Cultures typically use 10% to 20% fetal bovine serum (FBS) during post-thaw recovery. To prevent bovine immunoglobulins from contaminating purified reagents, production workflows transition adapted cells to chemically defined media.

Density Ceilings and Passage Routines

Hybridomas grow as nonadherent or semi-adherent cells requiring precise density monitoring:

• Target Density: Maintain working cultures between 1 × 10⁵ and 1 × 10⁶ viable cells/mL.
• Subculture Ratio: Dilute 1:3 to 1:6 every 2 to 4 days using established cell passaging protocols.
• Viability Ceilings: Densities above 2 × 10⁶ to 3 × 10⁶ cells/mL deplete nutrients rapidly, triggering severe viability loss.

Diagnostic Regulatory Standards

Monoclonal antibodies incorporated into in vitro diagnostic immunohistochemistry kits are regulated under FDA 21 CFR § 864.1860. Quality control mandates verifying clone isotype with standard antibody isotyping assays, confirming epitope specificity, and establishing lot-to-lot titer consistency.

Common misunderstandings

• Misunderstanding: Hybridomas are genetically stable indefinitely.
  Reality: Hybridomas are aneuploid fusion cells subject to spontaneous chromosome loss and drift. Non-producing revertants that lose heavy or light chain expression expend less metabolic energy and can outgrow producing cells during extended passaging (>20 passages). Early master banking and regular re-cloning are essential.
• Misunderstanding: All hybridomas secrete a single, uniform antibody.
  Reality: Sequencing studies demonstrate that approximately 31.9% of hybridomas express additional productive heavy or light chain transcripts from residual myeloma or B cell alleles, yielding multi-specific or aberrant antibody pairings.
• Misunderstanding: A viability drop 24 hours post-thaw signals batch failure.
  Reality: ATCC technical guidelines note that hybridomas undergo a predictable post-thaw recovery nadir ~24 hours after thawing due to cryopreservation stress, recovering viability over the following 48 to 72 hours.
• Misunderstanding: Maximum cell proliferation yields maximum antibody output.
  Reality: Bioprocess evaluations show an inverse relationship between cellular proliferation and specific antibody productivity (q_Ab, pg/cell/day). Peak antibody secretion predominantly occurs during late-log and stationary phases rather than rapid exponential division.

Frequently asked questions

What is a hybridoma cell?

A hybridoma is an engineered somatic hybrid cell produced by fusing an antibody-secreting B lymphocyte with an immortal myeloma cell, creating a continuous cell line that secretes identical monoclonal antibodies.

How does HAT medium select for hybridomas?

HAT medium uses aminopterin to block de novo nucleotide synthesis. HGPRT-deficient myeloma partners cannot utilize hypoxanthine for salvage and die. Primary B cells have HGPRT but senesce naturally within days. Only hybridomas survive because they inherit the functional HGPRT salvage enzyme from the B cell and immortality from the myeloma.

Why do hybridoma cell lines lose antibody productivity over time?

Hybridomas are aneuploid cells prone to chromosome loss. Over extended passaging, cells can lose immunoglobulin gene loci. Non-producing revertants replicate faster than antibody secretors, gradually overtaking the culture unless preserved in master cryobanks and periodically re-cloned.

What cryopreservation protocol preserves hybridoma stability?

ATCC protocols specify freezing cells during log phase at >90% viability. Cells are suspended at 5 × 10⁶ to 1 × 10⁷ cells/mL in medium with 5% to 10% DMSO, cooled at a controlled rate of −1°C per minute, and stored in liquid nitrogen vapor phase.

Sources

• ATCC. Animal Cell Culture Guide: Tips and Techniques for Continuous Cell Lines. American Type Culture Collection, Manassas, VA. URL: https://www.atcc.org/resources/culture-guides/animal-cell-culture-guide (accessed 2026-11-09).
• Popova, O., et al. (2026). Functional Parameters of Hybridoma Cells: Methods of Evaluation and Biotechnological Relevance. Antibodies, 15(4), 67. DOI: 10.3390/antib15040067. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13509340/ (accessed 2026-11-09).
• Lu, R. M., et al. (2025). Technologies for Monoclonal Antibody Discovery and Development. International Journal of Molecular Sciences, 26(21), 10470. DOI: 10.3390/ijms262110470. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12610488/ (accessed 2026-11-09).
• U.S. Food and Drug Administration / Legal Information Institute. 21 CFR § 864.1860: Immunohistochemistry Reagents and Kits. URL: https://www.law.cornell.edu/cfr/text/21/864.1860 (accessed 2026-11-09).